ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC By Ogkologos - May 21, 2026 226 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TOMBOLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... ESMO welcomes the adoption of European Parliament Report on Europe’s Beating Cancer Plan in the Committee on Public Health (SANT), calls for further EU... MOST POPULAR Benefits of Regular Breast Cancer Screening Outweigh Risks of Overdiagnosis, New... May 18, 2021 After Struggling With Chronic Illnesses Most of Her Life, This Author... June 21, 2021 Cancer in My Community: Working Toward Early Diagnosis for Children With... August 3, 2023 Targeted drug recommended to treat some advanced lung cancer patients November 25, 2021 Load more HOT NEWS ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report... Cancer in My Community: Addressing Regional Cancer Disparities in Peru FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and...
